Share on StockTwits

SciClone Pharmaceuticals (NASDAQ:SCLN) Director Nancy T. Chang bought 25,040 shares of the stock in a transaction dated Friday, August 15th. The shares were purchased at an average price of $6.00 per share, with a total value of $150,240.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

SciClone Pharmaceuticals (NASDAQ:SCLN) traded up 0.47% on Thursday, hitting $6.39. 261,360 shares of the company’s stock traded hands. SciClone Pharmaceuticals has a 1-year low of $4.24 and a 1-year high of $6.58. The stock has a 50-day moving average of $5.24 and a 200-day moving average of $4.91. The company has a market cap of $326.4 million and a P/E ratio of 15.14.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its earnings results on Monday, August 11th. The company reported $0.20 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.10. The company had revenue of $32.50 million for the quarter, compared to the consensus estimate of $33.40 million. During the same quarter last year, the company posted ($0.04) earnings per share. SciClone Pharmaceuticals’s revenue was up 10.9% compared to the same quarter last year. On average, analysts predict that SciClone Pharmaceuticals will post $0.49 earnings per share for the current fiscal year.

SciClone Pharmaceuticals, Inc (NASDAQ:SCLN) is a specialty pharmaceutical company.

Receive News & Ratings for SciClone Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.